Author:
Gross Christina,Berry-Kravis Elizabeth M,Bassell Gary J
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference218 articles.
1. (The annotated references were selected based on their importance for the development of therapeutic strategies for FXS. They describe: (1) the discovery of FXS phenotypes in animal models that proved to be useful to develop and/or evaluate therapeutic strategies, (2) rescue of FXS-associated phenotypes using either genetic or pharmacologic strategies in animal models, or (3) important clinical trials with FXS patients. The authors wish to note that this is not intended to depreciate the scientific value of the many excellent basic science studies that were not annotated.)
2. Adusei DC, Pacey LKK, Chen D, Hampson DR (2010). Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59: 167–171.
3. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ (2004). Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 24: 2648–2655.
4. Auerbach BD, Bear MF (2010). Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J Neurophysiol 104: 1047–1051.
5. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR et al (2010). Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet 87: 316–324.
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献